Menu

Challenges in Confirming Dr. Heidi Overton as FDA Commissioner

5 days ago 0

Dr. Heidi Overton, nominated by President Trump for the position of FDA commissioner, is encountering obstacles in securing enough support within the Senate Health, Education, Labor, and Pensions Committee. The vote on her nomination is set for Wednesday. However, she is struggling to gain backing, particularly from Republican members of the committee. If support is not garnered, her nomination may be rescinded. Democrat members are not expected to support her nomination either.

The White House is aware of the issue and is already evaluating other potential candidates. Some candidates have been considered to potentially serve in an acting role, bypassing the need for Senate confirmation. CBS News reached out to the White House but has not yet received a comment.

Overton’s nomination is facing hurdles primarily due to her stance on the FDA-approved chemical abortion drug, mifepristone, and her involvement in President Trump’s pro-vaping policies during her tenure on the Domestic Policy Council. Missouri Republican Senator Josh Hawley, among others, has expressed skepticism regarding Overton’s approach to conducting a safety study on mifepristone, which has been a priority for the Trump administration.

The anti-abortion group Susan B. Anthony has lobbied the Senate to delay Overton’s confirmation, advocating for a ban on mail orders of mifepristone. Additionally, two Republicans who support abortion access — Senators Susan Collins of Maine and Lisa Murkowski of Alaska — have not yet disclosed their voting intentions on Overton’s nomination. During the confirmation hearing, Murkowski questioned Overton about any potential restrictions on mifepristone, as it plays a role in more than half of the abortions performed in the United States.

There have been discussions within the administration about appointing an acting commissioner for the FDA, which would bypass the Senate confirmation process, crucial in the limited legislative window left this year.

Senator Roger Marshall of Kansas, a doctor, is reportedly interested in the FDA position. He recently lost his reelection bid against Democrat Adam Hamilton. Overton is currently one of the most prominent Trump nominees facing difficulty in gaining support during the final weeks of Republican control in Congress.

In another development, Hung Cao, nominated by Trump for Navy Secretary, underwent intense questioning concerning wartime operations management. Meanwhile, Eric Ueland’s nomination to lead the Government Accountability Office met with opposition from retiring Senator Thom Tillis, citing past involvement in executing budget cuts.

The FDA is currently led by acting Commissioner Kyle Diamantas following the dismissal of Marty Makary by the White House earlier this year. Sources attribute his ouster to tensions with the administration over flavored vaping products. Dr. Makary claimed that pressure from tobacco interests on the administration compelled him to permit fruit-flavored vapes, which often attract children, but did not comply.

In 2024, Trump emphasized saving vaping as part of his campaign. He described it as an alternative to smoking while downplaying associated health risks. Republican Senator Bill Cassidy of Louisiana, in a conversation with CBS’s “Face the Nation,” addressed whether Republicans could appoint a Senate-confirmed FDA commissioner before their Senate control concludes. Without such an appointment, the FDA may be overseen by successive acting commissioners, potentially subject to increased influence from the Health and Human Services Secretary.

Cassidy voiced concerns about Overton’s nomination due to her part in Trump’s stance to hinder childhood vaccine uptake. Despite ongoing discussions, he remains undecided on how he will vote in the committee he leads. Overton had previously supported Trump in signing an executive order regarding vaccines, during which Trump misattributed the measles, mumps, and rubella vaccine as “lethal,” without corrections from health officials.

Recently resigned health advocate Calley Means has urged blocking Overton’s confirmation. Despite criticisms tied to Trump policies, Overton’s advocates highlight her medical qualifications and endorsements from former FDA commissioners as evidence of her capability.

The committee vote for Overton, along with a few other health-related nominations, is still scheduled for Wednesday morning.

Leave a Reply

Leave a Reply

Your email address will not be published. Required fields are marked *